Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/5OmJHDYWmM https://t.co/iHsqlJ9wYl
Links:
Sandoz receives FDA approval for first and only denosumab biosimilars
https://bit.ly/4c5GHie
Mar-05-2024
